Charles River Laboratories Retained Earnings (Accumulated Deficit) 2010-2024 | CRL

Charles River Laboratories retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $2.123B, a 23.39% increase year-over-year.

  • Charles River Laboratories retained earnings (accumulated deficit) for 2023 were $1.887B, a 31.71% increase from 2022.
  • Charles River Laboratories retained earnings (accumulated deficit) for 2022 were $1.433B, a 46.1% increase from 2021.
  • Charles River Laboratories retained earnings (accumulated deficit) for 2021 were $0.981B, a 56.82% increase from 2020.

Charles River Laboratories Retained Earnings (Accumulated Deficit) 2010-2024 | CRL

  • Charles River Laboratories retained earnings (accumulated deficit) for 2023 were $1.887B, a 31.71% increase from 2022.
  • Charles River Laboratories retained earnings (accumulated deficit) for 2022 were $1.433B, a 46.1% increase from 2021.
  • Charles River Laboratories retained earnings (accumulated deficit) for 2021 were $0.981B, a 56.82% increase from 2020.